Broader Scope Needed for Unitaid AIDs Drug Patent Pool, Cipla Urges
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Just three weeks after Unitaid decided to move forward with a long-debated plan to establish patent pools for AIDS medicines, the owner of renowned Indian generics maker Cipla says the project needs a much wider scope and a lot more clarity if it is to have any effect
You may also be interested in...
A Closer Look: Gilead’s Viread Donation To China
Gilead’s decision to donate Viread to Chinese HIV patients came at a time when China was updating its compulsory license rules. The U.S. company may have also been thinking about the potential ramifications for hepatitis B, a much larger market in China.
China, Brazil Should Not Be In AIDS Drug Patent Pool, Gilead Says
HONG KONG - The number of partnerships among multinational pharmaceutical companies for HIV/AIDS drugs is on the rise, driven in part by the growing need for combination products to which no single company owns all the patents
China, Brazil Should Not Be In AIDS Drug Patent Pool, Gilead Says
HONG KONG - The number of partnerships among multinational pharmaceutical companies for HIV/AIDS drugs is on the rise, driven in part by the growing need for combination products to which no single company owns all the patents